Nabla Bio emerged from the lab of famed Harvard scientist George Church last year, and its antibody discovery technology has already led to five partnerships with pharma and biotech companies. The startup just closed an $11 million seed financing that will support further development of its technology.
Harvard University spinout GRO Biosciences has technology offering the potential for protein therapies that are safer and more effective than currently available biologic drugs. The startup's research is now backed by $25 million, a Series A financing round whose investors include the venture arm of Bayer.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Around 120,000 people are on an organ waiting list, but only 31,000 transplants were performed in 2015, according to organdonor.gov.
Other commercial tests only explore a small portion of the genome with gene panels - myGenome would essentially replace the need for any of those individually.